[Comparative efficiency of treatment with moxyfloxacin and lomefloxacin for generalized murine tuberculosis caused by drug-resistant Mycobacterium strains].
The antituberculous efficacy of the new fluoroquinolone agent moxyfloxacin was studied on a model of generalized murine tuberculosis caused by a multidrug-resistant Mycobacterium strain. There was evidence for the high therapeutic effect of moxyfloxacin and its advantages over the antituberculous agent lomefloxacin.
Mozhokina
G N
GN
Sokolova
G B
GB
Dashieva
D G
DG
Mikhaĭlova
L P
LP
Elistratova
N A
NA
D000818:Animals; D000995:Antitubercular Agents / Q000627:therapeutic use*; D001372:Aza Compounds / Q000627:therapeutic use*; D004195:Disease Models, Animal; D004359:Drug Therapy, Combination; D024841:Fluoroquinolones / Q000627:therapeutic use*; D008099:Liver / Q000382:microbiology / Q000473:pathology; D008168:Lung / Q000382:microbiology / Q000473:pathology; D051379:Mice; D000077266:Moxifloxacin; D009169:Mycobacterium tuberculosis / Q000187:drug effects / Q000302:isolation & purification / Q000472:pathogenicity*; D011804:Quinolines / Q000627:therapeutic use*; D015363:Quinolones / Q000627:therapeutic use*; D016896:Treatment Outcome; D018088:Tuberculosis, Multidrug-Resistant / Q000188:drug therapy* / Q000382:microbiology / Q000473:pathology
D000995:Antitubercular Agents; D001372:Aza Compounds; D024841:Fluoroquinolones; D011804:Quinolines; D015363:Quinolones; C053091:lomefloxacin; D000077266:Moxifloxacin